Study Evaluating the Effects of MOA-728 on Cardiac Repolarization in Healthy Subjects

This study has been completed.
Information provided by:
Salix Pharmaceuticals Identifier:
First received: February 9, 2007
Last updated: July 22, 2011
Last verified: July 2011

The purpose of the study is to assess the effects of MOA-728 on cardiac repolarization in healthy subjects.

Condition Intervention Phase
Drug: MOA-728
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo- and Moxifloxacin (Open-Label)-Controlled, 4-Period Crossover Study of the Effects of a Single Dose of MOA-728 Infused Intravenously on Cardiac Repolarization in Healthy Subjects

Further study details as provided by Salix Pharmaceuticals:

Primary Outcome Measures:
  • Cardiac repolarization will be assessed by the QTc interval in healthy subjects.

Study Start Date: March 2007
Study Completion Date: October 2007

Ages Eligible for Study:   18 Years to 50 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Generally healthy subjects men or women aged 18-50

Exclusion Criteria:

  • Any significant clinically important disease
  • Family history of long QT syndrome and/or sudden cardiac death
  • Allergy to moxifloxacin or the quinolone class of antibiotics
  Contacts and Locations
Please refer to this study by its identifier: NCT00434395

United States, Arizona
Phoenix, Arizona, United States, 85044
Sponsors and Collaborators
Salix Pharmaceuticals
Study Director: Jeff Cohn Salix Pharmaceuticals
  More Information

No publications provided

Responsible Party: Jeff Cohn, Salix Pharmaceuticals Identifier: NCT00434395     History of Changes
Other Study ID Numbers: 3200L2-104
Study First Received: February 9, 2007
Last Updated: July 22, 2011
Health Authority: United States: Food and Drug Administration processed this record on April 16, 2014